Skip to main content

Published locations for DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on

User login

  • Reset your password
  • /content/dlbcl-pfs-no-os-benefit-polatuzumab-vedotin-add
  • /hematologynews/article/250018/b-cell-lymphoma/dlbcl-pfs-no-os-benefit-polatuzumab-vedotin-add
  • /jcomjournal/article/250018/b-cell-lymphoma/dlbcl-pfs-no-os-benefit-polatuzumab-vedotin-add
  • /hematology-oncology/article/250018/b-cell-lymphoma/dlbcl-pfs-no-os-benefit-polatuzumab-vedotin-add
  • /b-cell-lymphoma-icymi/article/250018/b-cell-lymphoma/dlbcl-pfs-no-os-benefit-polatuzumab-vedotin-add